Novel glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonists and glucagon/GLP-1/glucose-dependent insulinotropic peptide (GIP) receptor triagonists are currently being developed to treat obesity and associated comorbidities (2-6). The gene discussed is GLP1R; the disease is Obesity.